tbuckley/cabot-search huggingface dataset:
Abstract 21067: Improvements in Regional Myocardial Function on 2D STE With Optimized Chelation in Patients With Thalassemia Major (TM)
Authors: Devyani Chowdhury, Najveen Alvi, Rebekah Tomredle, Bart Bijnens, Babar Hasan
Journal: Circulation (2017)

Intro: Thalassemia Major (TM) is characterized by recurrent blood transfusions leading to myocardial siderosis and complications including arrhythmias and heart failure. These can be reversible with adequate chelation. We explored the effect of improved chelation and subsequent cardiac T2* MRI (CMR) values on regional myocardial function assessed by 2D STE in setting of normal LVEF. Methods: Data was derived from TM patients recruited for the AMIT study (efficacy of amlodipine with chelation in reducing myocardial iron). All patients underwent echocardiographic imaging at baseline, 6 and 12 months. LSsys was extracted from basal, mid, and apical segments of the LV medial and lateral wall by 2D STE technique. A linear regression model was run to determine the effect of improved T2* in the setting of improved chelation on regional LSsys strain parameters. Results: Nineteen TM patients (11 males), median age 16 (8-21) yrs. All participants were transfused every 2-3 weeks. (median pre-transfusional Hb of 9.3 (8.3-10.8) mg/dL). T2* based chelation regimen was initiated at baseline and compliance to this regimen was gauged at regular clinical visits. 25 data points were available from interval 2D STE imaging for analysis. Medial basal LSsys (-17.3% ± 2.2) and lateral basal LSsys (-16.7% ± 4.4) strains were significantly lower than mean apical LSsys strains (-24.9% ± 4.0) (p &lt;0.01). With optimized improved chelation, we determined up to a 6.3% improvement was seen in LSsys basal septal and 6.7% improvement in LSsys apical septal for each 1 ms improvement in T2* (p values &lt; 0.05). Conclusion: 2D STE can help identify regional myocardial dysfunction prior to development of overt cardiac dysfunction. In patients with transfusion dependent TM, compliance to an optimized chelation regimen can help improve regional myocardial function prior to progression to systolic dysfunction and clinically symptomatic sideroblastic complications.
AB0600 Relevance of ophthalmoscopic evaluation in patients with systemic lupus erythematosus: underestimation of intraocular pressure values
Authors: M.C.D.F. Salgado, A.D.C.M. Paiva, Y.D.F.B. Chagas, J.L.P. Vaz, F.C. Freire, L.M. Arêas, F.C. Freire, V. Vigneron, Y.D.F.B. Chagas, J.L.P. Vaz, A. Vaz, V. Vigneron
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The evaluation of the size of the optic nerve papilla in ophthalmoscopy is an important tool for the diagnosis of glaucoma in individuals who do not present elevated intraocular pressure (IOP) levels. The calibration of the IOP is performed through Goldmann's tonometry, which consists of flattening the central cornea with a tonometer. Patients with Systemic Lupus Erythematosus (SLE) have circulating autoantibodies and immunocomplexes that alter corneal biomechanics, resulting in underestimated IOP values. <h3>Objectives</h3> To evaluate the IOP values and the presence of increased excavation in patients with SLE, reinforcing the importance of ophthalmoscopy in this population. <h3>Methods</h3> Descriptive study. Analysis of IOP measurement and papillary excavation of 50 SLE patients. <h3>Results</h3> All patients had IOP values within the normal range (8–21 mmHg). In a total of 100 eyes evaluated, four (4%) had increased papillary excavation. <h3>Conclusions</h3> Type I collagen is essential for the maintenance of biomechanical parameters and resistance of the cornea. At the corneal level, the activation of the complement system results in the lysis of type I collagen fibres, reducing corneal thickness and resistance. Therefore, IOP values for tonometry will be reduced and underestimated. Comparing the IOP values of SLE patients and healthy volunteers, there are lower results (p&lt;0.001) in lupus patients. In the present study, no patient had IOP changes. However, 4% of the eyes revealed increased excavation. These findings reflect the results of Yazici at al, and reinforce the importance of ophthalmoscopy in the screening of glaucoma in SLE patients. <h3>References</h3> [1] Silpa-archa S, Lee J, Foster CSl. Ocular manifestations in systemic lupus erythematosus. Br J Ophtalmol. 2016;100:135–41. [2] Moreira CA, Alves MR. Semiologia Básica em Oftalmologia. 3. ed. Rio de Janeiro: Cultura Médica: Guanabara Koogan; 2013. [3] Yazici AT, Kara N, Yüksel K, Altinkaynak H, Baz O, Bozkurt E, et al. The biomechanical properties of the cornea in patients with systemic lupus erythematosus. Eye. 2011;25:1005–9. <h3>Disclosure of Interest</h3> None declared
Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry
Authors: Ali Taher, Mohamed A Yassin, Zhijian Xiao, Hsin-An Hou, Tulin Tuglular, Vikram Mathews, Gerd Rippin, Islam Sadek, Asif Siddiqui, Raymond S Wong
Journal: Blood (2018)
Abstract 19032: Pancreatic Cancer Thromboembolic Outcomes: Rate of Thrombosis After Adenocarcinoma and Non-Adenocarcinoma Pancreatic Surgery
Authors: Luis A Diaz Quintero, Alfonso J Tafur, Harry E Fuentes, Susan Stocker, Mark S Talamonti
Journal: Circulation (2017)

Background: The rate of thrombosis after cancer surgery is high and cancer-associated thrombosis (CAT) is independently associated with mortality. Pancreatic cancer is most commonly associated with...
EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis
Authors: Renjie Wang, Sai Zhang, Xuyi Chen, Nan Li, Jianwei Li, Ruichao Jia, Yuanqing Pan, Haiqian Liang
Journal: Molecular Cancer (2018)

Abstract Background Circular RNAs (circRNAs) have been found to play critical roles in the development and progression of various cancers. However, little is known about the effects of the circular RNA network on glioblastoma multiforme (GBM). Methods A microarray was used to screen circRNA expression in GBM. Quantitative real-time PCR was used to detect the expression of circMMP9. GBM cells were transfected with a circMMP9 overexpression vector or siRNA, and cell proliferation, migration and invasion, as well as tumorigenesis in nude mice, were assessed to examine the effect of circMMP9 in GBM. Biotin-coupled miRNA capture, fluorescence in situ hybridization and luciferase reporter assays were conducted to confirm the relationship between circMMP9 and miR-124. Results In this study, we screened differentially expressed circRNAs and identified circMMP9 in GBM. We found that circMMP9 acted as an oncogene, was upregulated in GBM and promoted the proliferation, migration and invasion abilities of GBM cells. Next, we verified that circMMP9 served as a sponge that directly targeted miR-124; circMMP9 accelerated GBM cell proliferation, migration and invasion by targeting miR-124. Furthermore, we found that cyclin-dependent kinase 4 (CDK4) and aurora kinase A (AURKA) were involved in circMMP9/miR-124 axis-induced GBM tumorigenesis. Finally, we found that eukaryotic initiation factor 4A3 (eIF4A3), which binds to the MMP9 mRNA transcript, induced circMMP9 cyclization and increased circMMP9 expression in GBM. Conclusions Our findings indicate that eIF4A3-induced circMMP9 is an important underlying mechanism in GBM cell proliferation, invasion and metastasis through modulation of the miR-124 signaling pathway, which could provide pivotal potential therapeutic targets for the treatment of GBM. Graphical abstract
Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial
Authors: Muthiah Vaduganathan, Baljash Cheema, Erin Cleveland, Kamya Sankar, Haris Subacius, Gregg C Fonarow, Scott D Solomon, Eldrin F Lewis, Stephen J Greene, Aldo P Maggioni, Michael Böhm, Faiez Zannad, Javed Butler, Mihai Gheorghiade
Journal: Circulation (2017)

Background: The direct renin inhibitor, aliskiren, is known to reduce plasma renin activity (PRA), but whether the efficacy of aliskiren varies based on an individual’s baseline PRA in patients hospitalized for HF is presently unknown. We characterized the prognostic value of PRA and determined if this risk is modifiable with use of aliskiren. Methods: This pre-specified neurohormonal substudy of ASTRONAUT analyzed all patients hospitalized for HF with EF≤ 40% with available baseline PRA data (n=1,306, 80.9%). Risk associated with baseline PRA and short-term changes in PRA from baseline to 1-month was modeled with respect to 12-month clinical events. Results: Median baseline PRA was 3.0 (interquartile range 0.6-16.4) ng/mL/h with marked regional heterogeneity (P&lt;0.001); Figure . Aliskiren significantly reduced PRA early after treatment initiation through 12-month follow-up compared with placebo (P&lt;0.001). The lowest baseline PRA quartile (&lt;0.6 ng/mL/h) was independently predictive of lower all-cause mortality (adj. HR 0.50, 95% CI 0.31-0.81) and the composite of CV mortality and HF hospitalization (adj. HR 0.57, 95% CI 0.40-0.79); Table . Delta log-normalized PRA (from baseline to 1 month) was not predictive of either primary endpoint at 12 months (P≥0.43). The prognostic value of baseline PRA and short-term changes in PRA did not vary by randomization to aliskiren or placebo (interaction P≥0.13). Conclusions: PRA is reduced early and durably by aliskiren, but this did not appear to translate into improved clinical outcomes in ASTRONAUT. Baseline PRA or short-term reduction in PRA do not identify a subgroup which may preferentially benefit from direct renin inhibition.
Abstract 17026: Molar Ratio of N-terminal Fragment of Pro-B-type Natriuretic Peptide (BNP) to ProBNP Predicts Occurrence of Acute Kidney Injury in Patients With Acute Heart Failure
Authors: Hiroyuki Takahama, Seiji Takashio, Tomohiro Hayashi, Toshio Nishikimi, Yasuaki Nakagawa, Makoto Amaki, Takuya Hasegawa, Yasuo Sugano, Hideaki Kanzaki, Satoshi Yasuda, Kenji Kangawa, Naoto Minamino, Toshihisa Anzai
Journal: Circulation (2017)

Introduction: Early detection of worsening renal function in patients with acute heart failure (AHF) has not been established. Pro-B-type natriuretic peptide (BNP)1-108 is secreted into the blood a...
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
Authors: Natasha Szuber, Sravanthi Lavu, Mythri Mudireddy, Maura Nicolosi, Domenico Penna, Rangit R. Vallapureddy, Terra L. Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood Cancer Journal (2018)

Abstract   Background:  Subnormal serum erythropoietin (EPO) level is widely accepted as a minor diagnostic criterion for polycythemia vera (PV) and has retained its value in the revised 2016 World Health Organization (WHO) classification scheme of myeloid neoplasms (Blood. 2016;127:2391). While over 80% of PV patients exhibit subnormal EPO values (Haematologica. 2004;89:1194), very little is known about the incidence, phenotypic connotation, or prognostic significance of serum EPO levels in essential thrombocythemia (ET).  Methods:  Study patients were recruited from the Mayo Clinic, Rochester, MN, USA. Diagnosis of ET was in strict accordance with the 2016 WHO criteria (Blood. 2016;127:2391) and only patients with EPO measurements at diagnosis or during their chronic phase were considered under the following provisions: i) no evidence of myelofibrotic or leukemic transformation; ii) no treatment with cytoreductive agents at the time of sample collection (and for those with EPO sampling at diagnosis, no prior exposure to cytoreductive therapy); iii) no hemoglobin levels below sex-adjusted values for anemia; and iv) systematic exclusion of all cases of masked PV. Serum erythropoietin levels were measured using Mayo-verified standard immune-enzymatic assay consistent with CLIA requirements with reference range between 4-21 mIU/mL. Standard statistical methods and time-to-event curves prepared using the Kaplan-Meier method were used to compare EPO-stratified groups. The JMP® Pro 13.0.0 software package was used for all analyses (SAS Institute, Cary, NC, USA).  Results:  Among 177 informative ET patients (median age 51 years, range 18-88; 71% females), median serum EPO concentrations were 5.2 mIU/mL (range   Subnormal serum EPO levels clustered clinically with JAK2 mutations (95% vs 60%; p  While serum EPO level had no bearing on overall survival data (p=0.41) (Figure 1A), subnormal circulating EPO concentrations were significantly associated with superior myelofibrosis-free survival (p=0.02) (Figure 1B) but conversely, inferior polycythemia-free survival (p=0.03) (Figure 1C).  Conclusions:  We conclude that subnormal serum EPO levels are relatively frequent in ET, cluster with disease features that are reminiscent of polycythemia vera, and might be associated with a lower risk of fibrotic progression.          Download :  Download high-res image (700KB)       Download :  Download full-size image            Disclosures  No relevant conflicts of interest to declare.
An Asian consensus on standards of diagnostic upper endoscopy for neoplasia
Authors: Philip Wai Yan Chiu, Noriya Uedo, Rajvinder Singh, Takuji Gotoda, Enders Kwok Wai Ng, Kenshi Yao, Tiing Leong Ang, Shiaw Hooi Ho, Daisuke Kikuchi, Fang Yao, Rapat Pittayanon, Kenichi Goda, James Y W Lau, Hisao Tajiri, Haruhiro Inoue
Journal: Gut (2018)

This is a consensus developed by a group of expert endoscopists aiming to standardise the preparation, process and endoscopic procedural steps for diagnosis of early upper gastrointestinal (GI) cancers.The Delphi method was used to develop consensus statements through identification of clinical questions on diagnostic endoscopy. Three consensus meetings were conducted to consolidate the statements and voting. We conducted a systematic literature search on evidence for each statement. The statements were presented in the second consensus meeting and revised according to comments. The final voting was conducted at the third consensus meeting on the level of evidence and agreement.Risk stratification should be conducted before endoscopy and high risk endoscopic findings should raise an index of suspicion. The presence of premalignant mucosal changes should be documented and use of sedation is recommended to enhance detection of superficial upper GI neoplasms. The use of antispasmodics and mucolytics enhanced visualisation of the upper GI tract, and systematic endoscopic mapping should be conducted to improve detection. Sufficient examination time and structured training on diagnosis improves detection. Image enhanced endoscopy in addition to white light imaging improves detection of superficial upper GI cancer. Magnifying endoscopy with narrow-band imaging is recommended for characterisation of upper GI superficial neoplasms. Endoscopic characterisation can avoid unnecessary biopsy.This consensus provides guidance for the performance of endoscopic diagnosis and characterisation for early gastric and oesophageal neoplasia based on the evidence. This will enhance the quality of endoscopic diagnosis and improve detection of early upper GI cancers.
Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy
Authors: A. Anton, Z. Ballok, P. Bowden, T. Costello, L. Harewood, N. Corcoran, P. Dundee, J. Peters, N. Lawrentschuk, A. Troy, D. Webb, Y. Chan, A. See, S. Siva, D. Murphy, M.S. Hofman, B. Tran
Journal: Annals of Oncology (2018)
IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma
Authors: S. Qin, A.-L. Cheng, M.P. Ducreux, P.R. Galle, A. Zhu, T.-Y. Kim, D.-Z. Xu, W. Verret, J. Liu, R.S. Finn, M. Ikeda
Journal: Annals of Oncology (2018)
BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer
Authors: Barbara A Konkle, Amy Shapiro, Doris Quon, Janice Staber, Takashi Suzuki, Stacey Poloskey, Kara Rice, Suresh Katragadda, Dan Rudin, Joachim Fruebis
Journal: Blood (2018)
Insomnia as a predictor of mental disorders: A systematic review and meta-analysis
Authors: Elisabeth Hertenstein, Bernd Feige, Tabea Gmeiner, Christian Kienzler, Kai Spiegelhalder, Anna Johann, Markus Jansson-Fröjmark, Laura Palagini, Gerta Rücker, Dieter Riemann, Chiara Baglioni
Journal: Sleep Medicine Reviews (2018)
A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer
Authors: B. Han, K. Li, T. Chu, M. Bi, H. Zhang, Y. Yu, J. Shi, X. Zhang, Z. Chen, C. Han, T. Bai
Journal: Annals of Oncology (2019)

Background: QL1101 is a biosimilar molecule of bevacizumab (BEV,Avastin®) which is a monoclonal antibody (mAb) that binds and inhibits vascular endothelial growth factor (VEGF). The main purpose of the study is to evaluate whether the effectiveness of QL1101 is equivalent to that of Avastin®; the secondary purpose is to estimate the safety and immunogenicity. Methods: The study planed the recruitment of 512 patients with locally metastatic or recurrent non-squamous cell non-small cell lung cancer (NCT03169335). into QL1101 (test group) or Avastin® (control group) in combination with paclitaxel/carboplatin (paclitaxel 175mg/m2, carboplatin AUC=5) at a 1:1 ratio. QL1101 and Avastin (15mg/kg respectively) combined with chemotherapy, were given every 3 weeks as one treatment cycle for 6 cycles, then followed by QL1101 single-drug maintenance treatment. The primary endpoint was the best objective response rate (ORR) at week 18 evaluated by the blind independent imaging review committee. Results: A total of 675 subjects were screened and 532 were eventually treated, including 266 in the trial group and 266 in the control group. At week 18, the ORR of the QL1101 group and Avastin group, evaluated by the blind independent imaging review committee, were 52.26% (CR:0, PR:139) .and 56.02% (1 cases CR, 148 PR), respectively. Risk ratio (RR) value and 90%CI was 0.933(0.818-1.064), which met the prespecified equivalence margins (0.75-1.33).The median progression-free survival in the two groups was 7.72 and 8.25 months, respectively (HR: 1.111 (0.919—1.342)). The adverse reverse incidence of CTCAE ≥ 3 in the two groups were: 31.20 % in the experimental group and 24.06 % in the control group, respectively (p = 0.0808). The immunogenicity of the two groups was similar, and no neutralizing antibodies were detected. Conclusions: QL1101 and Avastin are equivalent in clinical efficacy in non-squamous cell non-small cell lung cancer patients, and the safety profile (including immunogenicity) is similar. There are no unexpected serious adverse reactions found. Clinical trial identification: NCT03169335; May 30, 2017. Legal entity responsible for the study: Qilu Pharmaceutical Co., Ltd, Shandong, People's Republic of China. Funding: Qilu Pharmaceutical Co., Ltd, Shandong, People's Republic of China. Disclosure: All authors have declared no conflicts of interest.
Antihelix/helix violaceous macules in Japanese patients with anti‐melanoma differentiation‐associated protein 5 ( <scp>MDA</scp> 5) antibody‐associated dermatomyositis
Authors: N. Okiyama, S. Inoue, A. Saito, Y. Nakamura, Y. Ishitsuka, Y. Fujisawa, R. Watanabe, M. Fujimoto
Journal: British Journal of Dermatology (2018)
Pooled RCTs: Adding LABAs to ICSs do not increase serious asthma events and reduce exacerbations
Authors: Jay I. Peters, Diego J. Maselli
Journal: Annals of Internal Medicine (2018)

ACP Journal Club20 November 2018Pooled RCTs: Adding LABAs to ICSs do not increase serious asthma events and reduce exacerbationsJay I. Peters, MD, Diego J. Maselli, MDJay I. Peters, MDUniversity of Texas Health at San Antonio, San Antonio, Texas, USA (J.I.P., D.J.M.)Search for more papers by this author, Diego J. Maselli, MDUniversity of Texas Health at San Antonio, San Antonio, Texas, USA (J.I.P., D.J.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-169-10-053 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationBusse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting β2-agonists. N Engl J Med. 2018;378:2497-505. https://pubmed.ncbi.nlm.nih.gov/29949492Clinical Impact RatingsGIM/FP/GP: Allerg & Immunol: Pulmonology: References1 Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-7. [PMID: 8098238] Google Scholar2 Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26. [PMID: 16424409] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas Health at San Antonio, San Antonio, Texas, USA (J.I.P., D.J.M.)This article was published at Annals.org on 6 November 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 November 2018Volume 169, Issue 10Page: JC53KeywordsAdolescentsAdverse eventsAsthmaFood and Drug AdministrationHospitalizationsIntubationRelative riskResearch fundingSafetySafety studies ePublished: 20 November 2018 Issue Published: 20 November 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...